Holen Sie sich die Stockscreener-App
2.40
7.01%
-0.1808
Handel nachbörslich:
2.40
Schlusskurs vom Vortag:
$2.5808
Offen:
$2.5
24-Stunden-Volumen:
9,741
Relative Volume:
0.31
Marktkapitalisierung:
$42.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.91M
KGV:
-13.06
EPS:
-0.1837
Netto-Cashflow:
-
1W Leistung:
+8.11%
1M Leistung:
+46.34%
6M Leistung:
+0.42%
1J Leistung:
+118.10%
1-Tages-Spanne:
$2.40
$2.50
1-Wochen-Bereich:
$2.20
$2.73
52-Wochen-Spanne:
$0.80
$12.68
Incannex Healthcare Inc Stock (IXHL) Company Profile
Firmenname
Incannex Healthcare Inc
Sektor
Telefon
61 409 840 786
Adresse
401 DOCKLANDS DRIVE, DOCKLANDS, VICTORIA
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Incannex Healthcare names Lou Barbato as chief medical officer - MSN
Incannex appoints new chief medical officer - Investing.com India
Incannex appoints new chief medical officer By Investing.com - Investing.com South Africa
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewswire
Incannex Healthcare Appoints Dr. Barbato as CMO - TipRanks
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks - Simply Wall St
Incannex Healthcare secures $3.3 million through debt financing By Investing.com - Investing.com Australia
Incannex Healthcare secures $3.3 million through debt financing - Investing.com
Incannex Healthcare secures A$6.9 million funding By Investing.com - Investing.com Australia
Incannex Healthcare secures A$6.9 million funding - Investing.com
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials - Sleep Review
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Invezz
R&D tax breaks buoy Incannex as losses narrow - Green Market Report
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Growth in Short Interest - Defense World
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - The Manila Times
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat
Incannex Secures Up to $60M in Financing to Support Clinical Trials - Sleep Review
Incannex secures financing deal valued at US$60 million - Mugglehead
Incannex $60 Million Deal With Arena For Late-Stage Drug TrialsIncannex Healthcare (NASDAQ:IXHL) - Benzinga
Incannex Healthcare secures $60 million funding via equity and debt - Investing.com
Incannex Healthcare secures $60 million funding via equity and debt By Investing.com - Investing.com UK
Incannex Healthcare lands $60 million financing deal - Green Market Report
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors - GlobeNewswire
Incannex secures $60 million in funding for clinical trials - Investing.com
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest - MarketBeat
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Virtu Financial LLC Buys New Shares in Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
4 Psychedelic Stocks to Consider as Clinical Trials Heat up - Investing.com
FDA Review of PsiGAD2 IND complete; clinical trial for - GlobeNewswire
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety - Benzinga
Incannex Healthcare gets FDA nod for Phase 2 trial - Green Market Report
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - StockTitan
Tidal Investments LLC Buys New Stake in Incannex Healthcare Inc. (NASDAQ:IXHL) - MarketBeat
Tidal Investments LLC Acquires Shares of 423,410 Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewswire
Head to Head Review: Zai Lab (NASDAQ:ZLAB) vs. Incannex Healthcare (NASDAQ:IXHL) - Defense World
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Down 69.0% in June - MarketBeat
7 Best Psychedelic Stocks in 2024 | Investing - U.S News & World Report Money
Patient Dosing Begins in Phase 2/3 Trial for OSA Drug Candidate IHL-42X - Sleep Review
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - Yahoo Finance
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder - Yahoo Finance
'Truly Remarkable’ Results Spur Incannex's Phase 2/3 Trials for Sleep Apnea Drug Candidate, Says CEO - Sleep Review
Finanzdaten der Incannex Healthcare Inc-Aktie (IXHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):